Antibodies directed against receptor tyrosine kinases

References

• Jiang X-R, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011; 10:101 - 11; http://dx.doi.org/10.1038/nrd3365; PMID: 21283105
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006; 56:226 - 43; http://dx.doi.org/10.3322/canjclin.56.4.226; PMID: 16870998
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127 - 37; http://dx.doi.org/10.1038/35052073; PMID: 11252954
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr.. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014; 79:34 - 74; http://dx.doi.org/10.1016/j.phrs.2013.11.002; PMID: 24269963
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39 - 51; http://dx.doi.org/10.1056/NEJMra043186; PMID: 17611206
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21:309 - 18; http://dx.doi.org/10.1016/S0149-2918(00)88288-0; PMID: 10211534
   PubMed Web of Science ®Google Scholar
• Nahta R. Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. ISRN Oncol 2012; 2012:428062; http://dx.doi.org/10.5402/2012/428062; PMID: 23227361
   PubMedGoogle Scholar
• McLarty K, Cornelissen B, Cai Z, Scollard DA, Costantini DL, Done SJ, Reilly RM. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 2009; 50:1340 - 8; http://dx.doi.org/10.2967/jnumed.109.062224; PMID: 19617342
   PubMed Web of Science ®Google Scholar
• Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 2011; 11:263 - 75; http://dx.doi.org/10.1586/era.10.226; PMID: 21342044
   PubMed Web of Science ®Google Scholar
• Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001; 61:4892 - 900; PMID: 11406568
   PubMed Web of Science ®Google Scholar
• Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer 2006; 94:259 - 67; http://dx.doi.org/10.1038/sj.bjc.6602930; PMID: 16404427
   PubMed Web of Science ®Google Scholar
• Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, Steiger C, Peters M, Baeuerle PA, da Silva AJ. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 2005; 92:342 - 9; PMID: 15655555
   PubMed Web of Science ®Google Scholar
• Kumar R, Mandal M, Vadlamudi R. New insights into anti-HER-2 receptor monoclonal antibody research. Semin Oncol 2000; 27:Suppl 11 84 - 91, discussion 92-100; PMID: 11236033
   PubMedGoogle Scholar
• Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62:4132 - 41; PMID: 12124352
   PubMed Web of Science ®Google Scholar
• Emlet DR, Brown KA, Kociban DL, Pollice AA, Smith CA, Ong BBL, Shackney SE. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 2007; 6:2664 - 74; http://dx.doi.org/10.1158/1535-7163.MCT-07-0079; PMID: 17938260
   PubMed Web of Science ®Google Scholar
• Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463 - 75; http://dx.doi.org/10.1038/nrc2656; PMID: 19536107
   PubMed Web of Science ®Google Scholar
• Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127 - 37; http://dx.doi.org/10.1016/S1535-6108(02)00097-1; PMID: 12204533
   PubMed Web of Science ®Google Scholar
• Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006; 55:717 - 27; http://dx.doi.org/10.1007/s00262-005-0058-x; PMID: 16151804
   PubMed Web of Science ®Google Scholar
• Hughes JB, Berger C, Rødland MS, Hasmann M, Stang E, Madshus IH. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol Cancer Ther 2009; 8:1885 - 92; http://dx.doi.org/10.1158/1535-7163.MCT-09-0291; PMID: 19584234
   PubMed Web of Science ®Google Scholar
• Metzger-Filho O, Winer EP, Krop I. Pertuzumab: optimizing HER2 blockade. Clin Cancer Res 2013; 19:5552 - 6; http://dx.doi.org/10.1158/1078-0432.CCR-13-0518; PMID: 23942091
   PubMed Web of Science ®Google Scholar
• Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68:5878 - 87; http://dx.doi.org/10.1158/0008-5472.CAN-08-0380; PMID: 18632642
   PubMed Web of Science ®Google Scholar
• Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006; 24:4317 - 23; http://dx.doi.org/10.1200/JCO.2005.04.8397; PMID: 16896008
   PubMed Web of Science ®Google Scholar
• Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69:9330 - 6; http://dx.doi.org/10.1158/0008-5472.CAN-08-4597; PMID: 19934333
   PubMed Web of Science ®Google Scholar
• Sak MM, Szymanska M, Bertelsen V, Hasmann M, Madshus IH, Stang E. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. Carcinogenesis 2013; 34:2031 - 8; http://dx.doi.org/10.1093/carcin/bgt173; PMID: 23698633
   PubMed Web of Science ®Google Scholar
• Fuentes G, Scaltriti M, Baselga J, Verma CS. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res 2011; 13:R54; http://dx.doi.org/10.1186/bcr2888; PMID: 21600050
   PubMedGoogle Scholar
• Kao H-F, Lin C-C, Yang JC-H. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Future Oncol 2013; 9:991 - 1003; http://dx.doi.org/10.2217/fon.13.56; PMID: 23837762
   PubMed Web of Science ®Google Scholar
• Warnault P, Yasri A, Coisy-Quivy M, Chevé G, Boriès C, Fauvel B, Benhida R. Recent advances in drug design of epidermal growth factor receptor inhibitors. Curr Med Chem 2013; 20:2043 - 67; http://dx.doi.org/10.2174/0929867311320160001; PMID: 23410174
   PubMed Web of Science ®Google Scholar
• Krawczyk P, Chocholska S, Milanowski J. Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer. Ann Univ Mariae Curie Sklodowska Med 2003; 58:113 - 7; PMID: 15314969
   PubMedGoogle Scholar
• Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ, Kang X. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int J Oncol 2009; 34:25 - 32; PMID: 19082474
   PubMed Web of Science ®Google Scholar
• Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1:1311 - 8; PMID: 9815926
   PubMed Web of Science ®Google Scholar
• Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:257 - 65; PMID: 10037173
   PubMed Web of Science ®Google Scholar
• Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007; 98:1275 - 80; http://dx.doi.org/10.1111/j.1349-7006.2007.00510.x; PMID: 17498200
   PubMed Web of Science ®Google Scholar
• Hsu Y-F, Ajona D, Corrales L, Lopez-Picazo JM, Gurpide A, Montuenga LM, Pio R. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Mol Cancer 2010; 9:139; http://dx.doi.org/10.1186/1476-4598-9-139; PMID: 20529262
   PubMed Web of Science ®Google Scholar
• Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson WE 3rd. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007; 13:6419 - 28; http://dx.doi.org/10.1158/1078-0432.CCR-07-0865; PMID: 17962339
   PubMed Web of Science ®Google Scholar
• Ashraf SQ, Nicholls AM, Wilding JL, Ntouroupi TG, Mortensen NJ, Bodmer WF. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc Natl Acad Sci U S A 2012; 109:21046 - 51; http://dx.doi.org/10.1073/pnas.1218750110; PMID: 23213241
   PubMed Web of Science ®Google Scholar
• Eller JL, Longo SL, Hicklin DJ, Canute GW. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery 2002; 51:1005 - 13, discussion 1013-4; PMID: 12234411
   PubMed Web of Science ®Google Scholar
• Hotz B, Keilholz U, Fusi A, Buhr HJ, Hotz HG. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. Gastric Cancer 2012; 15:252 - 64; http://dx.doi.org/10.1007/s10120-011-0102-9; PMID: 22011788
   PubMed Web of Science ®Google Scholar
• Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59:1935 - 40; PMID: 10213503
   PubMed Web of Science ®Google Scholar
• Modest DP, Stintzing S, Laubender RP, Neumann J, Jung A, Giessen C, Haas M, Aubele P, Schulz C, Boeck S, et al. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anticancer Drugs 2011; 22:913 - 8; http://dx.doi.org/10.1097/CAD.0b013e3283493160; PMID: 21795973
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne C-H. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48:1466 - 75; http://dx.doi.org/10.1016/j.ejca.2012.02.057; PMID: 22446022
   PubMed Web of Science ®Google Scholar
• Yang B-B, Lum P, Chen A, Arends R, Roskos L, Smith B, Pérez Ruixo JJ. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet 2010; 49:729 - 40; http://dx.doi.org/10.2165/11535970-000000000-00000; PMID: 20923247
   PubMed Web of Science ®Google Scholar
• Giannopoulou E, Antonacopoulou A, Matsouka P, Kalofonos HP. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res 2009; 29:5077 - 82; PMID: 20044619
   PubMed Web of Science ®Google Scholar
• Foon KA, Yang X-D, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58:984 - 90; http://dx.doi.org/10.1016/j.ijrobp.2003.09.098; PMID: 14967460
   PubMed Web of Science ®Google Scholar
• Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK, Parren PWHI, van de Winkel JGJ, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008; 68:4998 - 5003; http://dx.doi.org/10.1158/0008-5472.CAN-07-6226; PMID: 18593896
   PubMed Web of Science ®Google Scholar
• Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, Persaud K, Luna X, Ludwig DL, Kang X. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum Antibodies 2010; 19:89 - 99; PMID: 21178280
   PubMedGoogle Scholar
• Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PHC, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010; 184:512 - 20; http://dx.doi.org/10.4049/jimmunol.0900847; PMID: 19949082
   PubMed Web of Science ®Google Scholar
• Koch T, Derer S, Staudinger M, Rossen K, Glorius P, Peipp M, Kellner C, Kunzendorf U, Valerius T, Dechant M. Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysis. Am J Nephrol 2013; 38:379 - 87; http://dx.doi.org/10.1159/000355972; PMID: 24157422
   PubMed Web of Science ®Google Scholar
• Doi T, Tahara M, Yoshino T, Yamazaki K, Tamura T, Yamada Y, Yang B-B, Oliner KS, Otani S, Asahi D. Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 2011; 41:210 - 6; http://dx.doi.org/10.1093/jjco/hyq229; PMID: 21169348
   PubMed Web of Science ®Google Scholar
• Hocking CM, Price TJ. Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. Therap Adv Gastroenterol 2014; 7:20 - 37; http://dx.doi.org/10.1177/1756283X13498660; PMID: 24381645
   PubMed Web of Science ®Google Scholar
• Kumar SS, Price TJ, Mohyieldin O, Borg M, Townsend A, Hardingham JE. KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model. Gastrointest Cancer Res 2014; 7:23 - 6; PMID: 24558511
   PubMedGoogle Scholar
• Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002; 101:567 - 75; http://dx.doi.org/10.1002/ijc.10647; PMID: 12237899
   PubMed Web of Science ®Google Scholar
• Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 2009; 9:1199 - 206; http://dx.doi.org/10.1517/14712590903110709; PMID: 19624281
   PubMed Web of Science ®Google Scholar
• Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther 2011; 11:373 - 82; http://dx.doi.org/10.4161/cbt.11.4.14097; PMID: 21150278
   PubMed Web of Science ®Google Scholar
• Teresa Solomon M, Miranda N, Jorrín E, Chong I, Marinello JJ, Alert J, Lorenzo-Luaces P, Crombet T. Nimotuzumab in combination with radiotherapy in high grade glioma patients: A single institution experience. Cancer Biol Ther 2014; 15:504 - 9
   PubMed Web of Science ®Google Scholar
• Su D, Jiao S-C, Wang L-J, Shi W-W, Long Y-Y, Li J, Bai L. Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Tumour Biol 2014; 35:2313 - 8; http://dx.doi.org/10.1007/s13277-013-1306-x; PMID: 24142531
   PubMed Web of Science ®Google Scholar
• Gala K, Chandarlapaty S. Molecular Pathways: HER3 Targeted Therapy. Clin Cancer Res Off J Am Assoc Cancer Res 2014
   Google Scholar
• Li S, Kussie P, Ferguson KM. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008; 16:216 - 27; http://dx.doi.org/10.1016/j.str.2007.11.009; PMID: 18275813
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Tabernero J. Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Curr Opin Investig Drugs 2010; 11:1434 - 41; PMID: 21154125
   PubMed Web of Science ®Google Scholar
• Garrett TPJ, Burgess AW, Gan HK, Luwor RB, Cartwright G, Walker F, Orchard SG, Clayton AHA, Nice EC, Rothacker J, et al. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A 2009; 106:5082 - 7; http://dx.doi.org/10.1073/pnas.0811559106; PMID: 19289842
   PubMed Web of Science ®Google Scholar
• Gan HK, Burgess AW, Clayton AHA, Scott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 2012; 72:2924 - 30; http://dx.doi.org/10.1158/0008-5472.CAN-11-3898; PMID: 22659454
   PubMed Web of Science ®Google Scholar
• Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70:588 - 97; http://dx.doi.org/10.1158/0008-5472.CAN-09-1417; PMID: 20068188
   PubMed Web of Science ®Google Scholar
• Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, Wheeler DL. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia 2013; 15:1196 - 206; PMID: 24204198
   PubMed Web of Science ®Google Scholar
• Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res 2011; 13:R123; http://dx.doi.org/10.1186/bcr3069; PMID: 22129105
   PubMed Web of Science ®Google Scholar
• Schoeberl B, Faber AC, Li D, Liang M-C, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010; 70:2485 - 94; http://dx.doi.org/10.1158/0008-5472.CAN-09-3145; PMID: 20215504
   PubMed Web of Science ®Google Scholar
• Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res 2013; 19:610 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-12-2024; PMID: 23224399
   PubMed Web of Science ®Google Scholar
• Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res 2013; 73:6024 - 35; http://dx.doi.org/10.1158/0008-5472.CAN-13-1198; PMID: 23928993
   PubMed Web of Science ®Google Scholar
• Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res 2013; 73:6013 - 23; http://dx.doi.org/10.1158/0008-5472.CAN-13-1191; PMID: 23918797
   PubMed Web of Science ®Google Scholar
• Zhang L, Luan B, Yang K, Castanaro C, Papadopoulos N, Thurston G, Daly C. Abstract 2718: REGN1400, a fully-human ERBB3 antibody, potently inhibits tumor growth in preclinical models, both as a monotherapy and in combination with EGFR or HER2 blockers. Cancer Res 2012; 72:2718 - 2718; http://dx.doi.org/10.1158/1538-7445.AM2012-2718
   Google Scholar
• Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, Liu B. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Mol Cancer 2013; 12:134; http://dx.doi.org/10.1186/1476-4598-12-134; PMID: 24215614
   PubMed Web of Science ®Google Scholar
• Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee C-K, et al. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Res 2013; 15:R101; http://dx.doi.org/10.1186/bcr3563; PMID: 24168763
   PubMed Web of Science ®Google Scholar
• Mirschberger C, Schiller CB, Schräml M, Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G, Kolm I, et al. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res 2013; 73:5183 - 94; http://dx.doi.org/10.1158/0008-5472.CAN-13-0099; PMID: 23780344
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 2013; 39:793 - 801; http://dx.doi.org/10.1016/j.ctrv.2013.02.001; PMID: 23453860
   PubMed Web of Science ®Google Scholar
• Vearing C, Lee F-T, Wimmer-Kleikamp S, Spirkoska V, To C, Stylianou C, Spanevello M, Brechbiel M, Boyd AW, Scott AM, et al. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents. Cancer Res 2005; 65:6745 - 54; http://dx.doi.org/10.1158/0008-5472.CAN-05-0758; PMID: 16061656
   PubMed Web of Science ®Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4:915 - 25; http://dx.doi.org/10.1038/nrm1261; PMID: 14685170
   PubMed Web of Science ®Google Scholar
• Rosário M, Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol 2003; 13:328 - 35; http://dx.doi.org/10.1016/S0962-8924(03)00104-1; PMID: 12791299
   PubMed Web of Science ®Google Scholar
• Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res 2010; 70:639 - 45; http://dx.doi.org/10.1158/0008-5472.CAN-09-1121; PMID: 20068147
   PubMed Web of Science ®Google Scholar
• Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RAD, Kasman I, Mai E, Young J, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68:4360 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-07-5960; PMID: 18519697
   PubMed Web of Science ®Google Scholar
• Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A 2013; 110:E2987 - 96; http://dx.doi.org/10.1073/pnas.1302725110; PMID: 23882082
   PubMed Web of Science ®Google Scholar
• Roche provides update on phase III study of onartuzumab in people with specific type of lung cancer [Internet]. 2014. Available from: http://www.roche.com/media/media_releases/med-cor-2014-03-03.htm
   Google Scholar
• Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013; 19:1389 - 400; http://dx.doi.org/10.1038/nm.3388; PMID: 24202392
   PubMed Web of Science ®Google Scholar
• Goetsch L, Broussas M, Fabre-Lafay S, Robert A, Lepecquet A-M, Gonzalez A, Wurch T, Bailly C, Corvaia N. Abstract 2448: h224G11, a humanized whole antibody targeting the c-Met receptor, induces c-Met down-regulation and triggers ADCC functions. Cancer Res 2011; 70:2448 - 2448; http://dx.doi.org/10.1158/1538-7445.AM10-2448
   Google Scholar
• Zeng W, Yan L, Peek V, Wortinger M, Tetreault J, Xia J, Chow C-K, Manro JR, Stephens JR, Weir SN, et al. Abstract 2734: c-Met antibody LY2875358 (LA480) shows differential antitumor effects in non-small cell lung cancer. Cancer Res 2012; 72:2734 - 2734; http://dx.doi.org/10.1158/1538-7445.AM2012-2734
   Google Scholar
• Goetsch L, Gonzalez A, Geronimi F, Fabre-Lafay S, Broussas M, Lepecquet A-M, Wurch T. corvaia N, Bailly C. Abstract B127: Single or combined in vivo therapies of cancer with h224G11, a humanized antibody targeting the c-Met receptor. Mol Cancer Ther 2009; 8:B127 - 127; http://dx.doi.org/10.1158/1535-7163.TARG-09-B127
   Google Scholar
• Yao H-P, Zhou Y-Q, Zhang R, Wang M-H. MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer 2013; 13:466 - 81; http://dx.doi.org/10.1038/nrc3545; PMID: 23792360
   PubMed Web of Science ®Google Scholar
• Wang M-H, Padhye SS, Guin S, Ma Q, Zhou YQ. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy. Acta Pharmacol Sin 2010; 31:1181 - 8; http://dx.doi.org/10.1038/aps.2010.106; PMID: 20694025
   PubMed Web of Science ®Google Scholar
• Zou Y, Howell GM, Humphrey LE, Wang J, Brattain MG. Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi). PLoS One 2013; 8:e69992; http://dx.doi.org/10.1371/journal.pone.0069992; PMID: 23922886
   PubMedGoogle Scholar
• Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6:1 - 12; http://dx.doi.org/10.1158/1535-7163.MCT-06-0080; PMID: 17237261
   PubMed Web of Science ®Google Scholar
• Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996; 68:183 - 223; http://dx.doi.org/10.1016/S0065-230X(08)60354-1; PMID: 8712068
   PubMed Web of Science ®Google Scholar
• Grothey A, Voigt W, Schöber C, Müller T, Dempke W, Schmoll HJ. The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol 1999; 125:166 - 73; http://dx.doi.org/10.1007/s004320050259; PMID: 10235470
   PubMed Web of Science ®Google Scholar
• Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater?. J Natl Cancer Inst 2012; 104:975 - 81; http://dx.doi.org/10.1093/jnci/djs258; PMID: 22761272
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13:5549s - 55s; http://dx.doi.org/10.1158/1078-0432.CCR-07-1109; PMID: 17875788
   PubMed Web of Science ®Google Scholar
• Beltran PJ, Mitchell P, Chung Y-A, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009; 8:1095 - 105; http://dx.doi.org/10.1158/1535-7163.MCT-08-1171; PMID: 19366899
   PubMed Web of Science ®Google Scholar
• Gao J, Chang YS, Jallal B, Viner J. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 2012; 72:3 - 12; http://dx.doi.org/10.1158/0008-5472.CAN-11-0550; PMID: 22215692
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu S. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther 2010; 12:361 - 71; PMID: 20521225
   PubMed Web of Science ®Google Scholar
• Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 2008; 6:1795 - 806; http://dx.doi.org/10.1158/1541-7786.MCR-08-0244; PMID: 19074825
   PubMed Web of Science ®Google Scholar
• Xi H-Q, Wu X-S, Wei B, Chen L. Eph receptors and ephrins as targets for cancer therapy. J Cell Mol Med 2012; 16:2894 - 909; http://dx.doi.org/10.1111/j.1582-4934.2012.01612.x; PMID: 22862837
   PubMed Web of Science ®Google Scholar
• Nievergall E, Saunders T, Lackmann M. Targeting of EPH receptor tyrosine kinases for anticancer therapy. Crit Rev Oncog 2012; 17:211 - 32; http://dx.doi.org/10.1615/CritRevOncog.v17.i2.60; PMID: 22471709
   PubMedGoogle Scholar
• Boyd AW, Bartlett PF, Lackmann M. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov 2014; 13:39 - 62; http://dx.doi.org/10.1038/nrd4175; PMID: 24378802
   PubMed Web of Science ®Google Scholar
• Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther 2013; 13:1187 - 96; http://dx.doi.org/10.1517/14712598.2013.810717; PMID: 23803182
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 2013; 153:13 - 9; http://dx.doi.org/10.1093/jb/mvs136; PMID: 23172303
   PubMed Web of Science ®Google Scholar
• Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B, Wu Y. Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1). Cancer 2010; 116:Suppl 1027 - 32; http://dx.doi.org/10.1002/cncr.24789; PMID: 20127948
   PubMed Web of Science ®Google Scholar
• Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009; 10:597 - 605; PMID: 19513949
   PubMed Web of Science ®Google Scholar
• Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 2009; 23:289 - 304; http://dx.doi.org/10.2165/11317600-000000000-00000; PMID: 19754219
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, et al, REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383:31 - 9; http://dx.doi.org/10.1016/S0140-6736(13)61719-5; PMID: 24094768
   PubMed Web of Science ®Google Scholar
• Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu Y, et al. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer 2014; Forthcoming http://dx.doi.org/10.1002/cncr.28634; PMID: 24577874
   PubMed Web of Science ®Google Scholar
• Lee SH. Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2). Arch Pharm Res 2011; 34:1223 - 6; http://dx.doi.org/10.1007/s12272-011-0821-9; PMID: 21910042
   PubMed Web of Science ®Google Scholar
• Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, Holnthoner W, Heloterä H, Holopainen T, Jeltsch M, et al. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 2010; 18:630 - 40; http://dx.doi.org/10.1016/j.ccr.2010.11.001; PMID: 21130043
   PubMed Web of Science ®Google Scholar
• Persaud K, Tille J-C, Liu M, Zhu Z, Jimenez X, Pereira DS, Miao H-Q, Brennan LA, Witte L, Pepper MS, et al. Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C. J Cell Sci 2004; 117:2745 - 56; http://dx.doi.org/10.1242/jcs.01138; PMID: 15150322
   PubMed Web of Science ®Google Scholar
• Goldman J, Rutkowski JM, Shields JD, Pasquier MC, Cui Y, Schmökel HG, Willey S, Hicklin DJ, Pytowski B, Swartz MA. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. FASEB J 2007; 21:1003 - 12; http://dx.doi.org/10.1096/fj.06-6656com; PMID: 17210781
   PubMed Web of Science ®Google Scholar
• Liang J, Wu Y-L, Chen B-J, Zhang W, Tanaka Y, Sugiyama H. The C-kit receptor-mediated signal transduction and tumor-related diseases. Int J Biol Sci 2013; 9:435 - 43; http://dx.doi.org/10.7150/ijbs.6087; PMID: 23678293
   PubMed Web of Science ®Google Scholar
• Ostman A, Heldin C-H. PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007; 97:247 - 74; http://dx.doi.org/10.1016/S0065-230X(06)97011-0; PMID: 17419949
   PubMed Web of Science ®Google Scholar
• Shah GD, Loizos N, Youssoufian H, Schwartz JD, Rowinsky EK. Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha. Cancer 2010; 116:Suppl 1018 - 26; http://dx.doi.org/10.1002/cncr.24788; PMID: 20127943
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, Nippgen J, Amato R. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2014; 73:595 - 604; http://dx.doi.org/10.1007/s00280-014-2389-9; PMID: 24452395
   PubMed Web of Science ®Google Scholar
• Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013; 3:264 - 79; http://dx.doi.org/10.1158/2159-8290.CD-12-0362; PMID: 23418312
   PubMed Web of Science ®Google Scholar
• Liang G, Liu Z, Wu J, Cai Y, Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci 2012; 33:531 - 41; http://dx.doi.org/10.1016/j.tips.2012.07.001; PMID: 22884522
   PubMed Web of Science ®Google Scholar
• Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010; 125:105 - 17; http://dx.doi.org/10.1016/j.pharmthera.2009.10.001; PMID: 19874848
   PubMed Web of Science ®Google Scholar
• Tiong KH, Mah LY, Leong C-O. Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis 2013; 18:1447 - 68; http://dx.doi.org/10.1007/s10495-013-0886-7; PMID: 23900974
   PubMed Web of Science ®Google Scholar
• Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 2013; 73:1649 - 57; http://dx.doi.org/10.1158/0008-5472.CAN-12-4697; PMID: 23467610
   PubMed Web of Science ®Google Scholar
• Eroglu Z, Stein CA, Pal SK. Targeting angiopoietin-2 signaling in cancer therapy. Expert Opin Investig Drugs 2013; 22:813 - 25; http://dx.doi.org/10.1517/13543784.2013.793306; PMID: 23621441
   PubMed Web of Science ®Google Scholar
• Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, Akhondi M, Lagercrantz S, Larsson C, Osterborg A, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 2008; 123:1190 - 5; http://dx.doi.org/10.1002/ijc.23587; PMID: 18546292
   PubMed Web of Science ®Google Scholar
• Rebagay G, Yan S, Liu C, Cheung N-K. ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy. Front Oncol 2012; 2:34; http://dx.doi.org/10.3389/fonc.2012.00034; PMID: 22655270
   PubMedGoogle Scholar
• Carpenter EL, Haglund EA, Mace EM, Deng D, Martinez D, Wood AC, Chow AK, Weiser DA, Belcastro LT, Winter C, et al. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene 2012; 31:4859 - 67; http://dx.doi.org/10.1038/onc.2011.647; PMID: 22266870
   PubMed Web of Science ®Google Scholar
• Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013; 13:685 - 700; http://dx.doi.org/10.1038/nrc3580; PMID: 24060861
   PubMed Web of Science ®Google Scholar
• Linger RMA, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008; 100:35 - 83; http://dx.doi.org/10.1016/S0065-230X(08)00002-X; PMID: 18620092
   PubMed Web of Science ®Google Scholar
• Nguyen K-Q, Tsou W-I, Kotenko S, Birge RB. TAM receptors in apoptotic cell clearance, autoimmunity, and cancer. Autoimmunity 2013; 46:294 - 7; http://dx.doi.org/10.3109/08916934.2013.794515; PMID: 23662598
   PubMed Web of Science ®Google Scholar
• Demarest SJ, Gardner J, Vendel MC, Ailor E, Szak S, Huang F, Doern A, Tan X, Yang W, Grueneberg DA, et al. Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines. Biochemistry 2013; 52:3102 - 18; http://dx.doi.org/10.1021/bi301588c; PMID: 23570341
   PubMed Web of Science ®Google Scholar
• Linger RMA, Keating AK, Earp HS, Graham DK. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets 2010; 14:1073 - 90; http://dx.doi.org/10.1517/14728222.2010.515980; PMID: 20809868
   PubMed Web of Science ®Google Scholar
• Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 2011; 10:1763 - 73; http://dx.doi.org/10.1158/1535-7163.MCT-11-0116; PMID: 21933973
   PubMed Web of Science ®Google Scholar
• Cook RS, Jacobsen KM, Wofford AM, DeRyckere D, Stanford J, Prieto AL, Redente E, Sandahl M, Hunter DM, Strunk KE, et al. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. J Clin Invest 2013; 123:3231 - 42; http://dx.doi.org/10.1172/JCI67655; PMID: 23867499
   PubMed Web of Science ®Google Scholar
• Cummings CT, Deryckere D, Earp HS, Graham DK. Molecular pathways: MERTK signaling in cancer. Clin Cancer Res 2013; 19:5275 - 80; http://dx.doi.org/10.1158/1078-0432.CCR-12-1451; PMID: 23833304
   PubMed Web of Science ®Google Scholar
• Linger RMA, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DHG, Lu X, Barón AE, Franklin WA, Merrick DT, et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 2013; 32:3420 - 31; http://dx.doi.org/10.1038/onc.2012.355; PMID: 22890323
   PubMed Web of Science ®Google Scholar
• Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon S-J, Park BM, Park E, Bae JH, Choi C-M, et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res 2014; 74:253 - 62; http://dx.doi.org/10.1158/0008-5472.CAN-13-1103; PMID: 24165158
   PubMed Web of Science ®Google Scholar
• Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S, Auberger P. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget 2011; 2:874 - 85; PMID: 22141136
   PubMed Web of Science ®Google Scholar
• Hong C-C, Lay J-D, Huang J-S, Cheng A-L, Tang J-L, Lin M-T, Lai G-M, Chuang S-E. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 2008; 268:314 - 24; http://dx.doi.org/10.1016/j.canlet.2008.04.017; PMID: 18502572
   PubMed Web of Science ®Google Scholar
• Li Y, Ye X, Tan C, Hongo J-A, Zha J, Liu J, Kallop D, Ludlam MJC, Pei L. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 2009; 28:3442 - 55; http://dx.doi.org/10.1038/onc.2009.212; PMID: 19633687
   PubMed Web of Science ®Google Scholar
• Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, Weimer R, Wu Y, Pei L. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 2010; 29:5254 - 64; http://dx.doi.org/10.1038/onc.2010.268; PMID: 20603615
   PubMed Web of Science ®Google Scholar
• Leconet W, Larbouret C, Chardès T, Thomas G, Neiveyans M, Busson M, Jarlier M, Radosevic-Robin N, Pugnière M, Bernex F, et al. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene 2013; Forthcoming http://dx.doi.org/10.1038/onc.2013.487; PMID: 24240689
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7:493 - 507; http://dx.doi.org/10.1038/nrclinonc.2010.97; PMID: 20551942
   PubMed Web of Science ®Google Scholar
• Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 2009; 15:7479 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-09-0636; PMID: 20008848
   PubMed Web of Science ®Google Scholar
• Thery J-C, Spano J-P, Azria D, Raymond E, Penault Llorca F. Resistance to human epidermal growth factor receptor type 2-targeted therapies. Eur J Cancer 2014; 50:892 - 901; http://dx.doi.org/10.1016/j.ejca.2014.01.003; PMID: 24462377
   PubMed Web of Science ®Google Scholar
• Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472 - 86; http://dx.doi.org/10.1016/j.ccr.2011.09.003; PMID: 22014573
   PubMed Web of Science ®Google Scholar
• Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2013; 73:824 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-12-1611; PMID: 23172311
   PubMed Web of Science ®Google Scholar
• Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther 2014; 13:410 - 25; http://dx.doi.org/10.1158/1535-7163.MCT-13-0255; PMID: 24282274
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Salat C, Lindhofer H, Menzel H, Untch M, Kahlert S, Konecny G, Sauer H, Ledderose G, Heinemann V, et al. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study. Anticancer Res 2005; 25:3047 - 54; PMID: 16080564
   PubMed Web of Science ®Google Scholar
• Hess J, Ruf P, Lindhofer H. Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity. Future Oncol 2012; 8:73 - 85; http://dx.doi.org/10.2217/fon.11.138; PMID: 22149036
   PubMed Web of Science ®Google Scholar
• Diermeier-Daucher S, Ortmann O, Buchholz S, Brockhoff G. Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs 2012; 4:614 - 22; http://dx.doi.org/10.4161/mabs.21003; PMID: 22820509
   PubMed Web of Science ®Google Scholar
• Schroeder P, Lindemann C, Dettmar K, Brieger J, Gosepath J, Pogorzelski B, Seimetz D, Atz J. Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Clin Transl Oncol 2011; 13:889 - 98; http://dx.doi.org/10.1007/s12094-011-0751-5; PMID: 22126733
   PubMed Web of Science ®Google Scholar
• Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 2013; 13:663 - 73; http://dx.doi.org/10.1038/nrc3559; PMID: 23949426
   PubMed Web of Science ®Google Scholar
• Emde A, Pradeep C-R, Ferraro DA, Ben-Chetrit N, Sela M, Ribba B, Kam Z, Yarden Y. Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth. Oncogene 2011; 30:1631 - 42; http://dx.doi.org/10.1038/onc.2010.547; PMID: 21132012
   PubMed Web of Science ®Google Scholar
• Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A 2010; 107:13252 - 7; http://dx.doi.org/10.1073/pnas.0913476107; PMID: 20616078
   PubMed Web of Science ®Google Scholar
• Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 2011; 17:5060 - 70; http://dx.doi.org/10.1158/1078-0432.CCR-10-2927; PMID: 21700765
   PubMed Web of Science ®Google Scholar
• Dong J, Demarest SJ, Sereno A, Tamraz S, Langley E, Doern A, Snipas T, Perron K, Joseph I, Glaser SM, et al. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther 2010; 9:2593 - 604; http://dx.doi.org/10.1158/1535-7163.MCT-09-1018; PMID: 20716637
   PubMed Web of Science ®Google Scholar
• Cante D, La Porta MR, Franco P, Sciacero P, Girelli GF, Marra A, Numico G, Denaro N, Russi EG, Ricardi U. Management of ‘in-field’ skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy. Oncology 2013; 85:257 - 61; http://dx.doi.org/10.1159/000355579; PMID: 24192693
   PubMed Web of Science ®Google Scholar
• Drachman JG, Senter PD. Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer. Hematology Am Soc Hematol Educ Program 2013; 2013:306 - 10; http://dx.doi.org/10.1182/asheducation-2013.1.306; PMID: 24319196
   PubMedGoogle Scholar
• Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho S-Y, Li L, Kaufman S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006; 66:1721 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-05-3329; PMID: 16452232
   PubMed Web of Science ®Google Scholar
• Gao J, Chesebrough JW, Cartlidge SA, Ricketts S-A, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 2011; 71:1029 - 40; http://dx.doi.org/10.1158/0008-5472.CAN-10-2274; PMID: 21245093
   PubMed Web of Science ®Google Scholar